Medical Devices; Exemptions From Premarket Notification: Certain Class II Devices; Request for Comments

Enrique A Gonzalez Guerra expresses concern over the negative economic impact caused by the elimination of the 510(k) clearance requirement for certain Class II medical devices. He argues that the lack of timely information and transparency regarding these changes has hindered his ability to work and calls for better communication in the regulatory process.

Gary L. Hardy opposes the FDA's proposal to remove the 510(k) exemption for devices used in federally regulated drug testing programs. He argues that the current requirement ensures assay accuracy and public safety, and he requests that the FDA provide evidence of safety, define replacement standards, and engage with stakeholders before proceeding.

A former DOT Substance Abuse Professional (SAP) opposes the removal of the 510(k) clearance requirement for federally regulated drug testing programs. The commenter argues that removing this requirement could lead to the use of poorly administered and deficient testing services, potentially compromising public safety.

A commercial driver with a HazMat endorsement opposes the proposal to remove the FDA 510(k) clearance requirement for drug testing assays. The commenter argues that maintaining strict oversight and reliable testing standards is essential for ensuring highway safety and preventing impaired driving among commercial drivers.

The commenter expresses concern that exempting certain Class II medical devices from formal FDA premarket notification will lead to inconsistent performance and reliability. They argue that relying on manufacturer self-assessment could result in inaccurate data, leading to significant legal, safety, and compliance issues in federally regulated programs.